Antibody (11C7) anti Nogo-A and its pharmaceutical use
This invention relates to molecules, such as for example monoclonal antibodies or Fab fragments thereof, which are capable of binding to the human NogoA polypeptide or human NiG or human NiG- or human NogoA_623-640 with a dissociation constant, 1000 nM; polynucleotides encoding such a binding molecule; an expression vector comprising such polynucleotides; the use of such a binding molecule in the treatment of nerve repair, a pharmaceutical composition comprising such a binding molecule; and to a method of treatment of diseases associated with nerve repair.
1. A method for inducing or enhancing nerve repair comprising administering to a subject in need of such treatment an isolated human Nogo A623-640 binding molecule which comprises a heavy chain variable domain or fragment thereof, and a light chain variable domain or fragment thereof, wherein said heavy chain variable domain or fragment thereof, comprises in sequential order the amino acid sequences of SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10; and wherein said light chain variable domain or fragment thereof comprises in sequential order the amino acid sequences of SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13.
2. A method of treatment of spinal chord injury in a subject in need of such treatment comprising administering to the subject an isolated human Nogo A623-640 binding molecule which comprises a heavy chain variable domain or fragment thereof, and a light chain variable domain or fragment thereof, wherein said heavy chain variable domain or fragment thereof, comprises in sequential order the amino acid sequences of SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10; and wherein said light chain variable domain or fragment thereof comprises in sequential order the amino acid sequences of SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13.